Pulsed-dye laser as an adjuvant treatment for discoid lupus erythematosus: a randomized, controlled trial

Rerknimitr, Pawinee; Tekacharin, Nucharin; Panchaprateep, Ratchathorn; Wititsuwannakul, Jade; Tangtanatakul, Pattarin; Hirankarn, Nattiya; Asawanonda, Pravit

doi:10.1080/09546634.2018.1468063

Cited by 19 publications

(20 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Yelamos et al found that using PDL in conjunction with hydroxychloroquine (which had not resolved the lesions as a monotherapy) in fact cured one child's cutaneous lupus on the dorsi of their hands with no recurrence at 2 years . Several other studies have also shown PDL to be effective both as an adjuvant therapy and monotherapy in cutaneous lupus.…”

Section: Sarcoid and Cutaneous Lupusmentioning

confidence: 99%

“…Rerknimitr et al carried out a double‐blind RCT in 48 discoid lupus lesions which were randomized to either receive 595‐nm PDL or no treatment 4 weekly for 4 months. Lesions treated with PDL improved and post‐PDL histology showed molecular changes found in disease remission pointing to the molecular effects of PDL on the disease . Al‐Niaimi et al found that individual telangiectasia in sarcoid can be safely and effectively treated with some improvement in lupus pernio and plaques with a vascular component …”

Section: Sarcoid and Cutaneous Lupusmentioning

confidence: 99%

See 1 more Smart Citation

Nonvascular uses of pulsed dye laser in clinical dermatology

Forbat

Al‐Niaimi

2019

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Lasers are fast becoming the vogue of dermatology ranging from ablative, nonablative, fractional photothermolysis to vascular lasers. There are a range of vascular lasers including potassium titanyl phosphate (KTP 532 nm), pulsed dye laser (PDL −595 nm), diode (810 nm), and Nd:YAG (1064 nm). PDL is a laser that emits yellow light using Rhodamine dye as it is lasing medium. Typical vascular lesions which are treated by PDL include port wine stain, hemangioma, telangiectasia, spider angioma, and rosacea. This article focuses on the use of PDL beyond primary vascular conditions. We review the evidence, or lack thereof, of the use of PDL in acne vulgaris, scars, striae, warts, molluscum, psoriasis, rejuvenation, basal cell carcinoma (BCC), and miscellaneous dermatological sequelae. K E Y W O R D Sacne, laser, nonvascular, psoriasis, pulsed dye, scar

show abstract

Section: Sarcoid and Cutaneous Lupusmentioning

confidence: 99%

Section: Sarcoid and Cutaneous Lupusmentioning

confidence: 99%

Nonvascular uses of pulsed dye laser in clinical dermatology

Forbat

Al‐Niaimi

2019

J of Cosmetic Dermatology

View full text Add to dashboard Cite

show abstract

“…Moreover, in a prospective study of 12 DLE patients with mild disease (baseline CLASI activity score 3-5), baseline CLASI activity significantly decreased after PDL, from a mean (SEM) of 4.4 ± 0.2 to 1.3 ± 0.3 after followup (p < 0.001) [120]. However, in a recent RCT involving 48 lesions in 9 DLE patients, no difference was seen in CLASI improvement with PDL as compared with the control [121].…”

Section: Pulsed Dye Laser (Pdl)mentioning

confidence: 92%

Current Concepts and Future Approaches in the Treatment of Cutaneous Lupus Erythematosus: A Comprehensive Review

Chasset

Françès

2019

Drugs

View full text Add to dashboard Cite

Standard treatment of cutaneous lupus erythematosus (CLE) includes preventive measures such as smoking cessation and photoprotection associated with topical therapies and antimalarial agents, which are recommended as first-line systemic treatment. In more severe disease, alternative therapeutic options include immunosuppressive and immunomodulatory drugs. Recently, the development of specific tools to assess CLE activity and the publication of European CLE guidelines have improved the management of CLE. Moreover, several biologic agents are currently studied specifically in CLE or in systemic lupus erythematosus with assessment of skin involvement and may be promising therapies. However, improvement of the management of CLE remains a major unmet need. In this review, we summarize current concepts in the management of CLE as well as future approaches for more targeted treatments. Key points:  Some targeted agents that have shown some promise in skin manifestations with systemic lupus erythematosus.  Future studies are needed specifically for cutaneous lupus erythematosus (CLE), with responses for each of the CLE subtypes reported separately.

show abstract

“…At each visit, a number of objective measurements were carried out including erythema index, measured by DSMII ColorMeter (Cortex technology, Hadsund, Denmark) and papulopustular lesion count. In addition, clinical photographs were taken by Visia (Canfield, NJ) and the photographs were evaluated at the end of the study by three independent dermatologists to obtain a physician global assessment (PGA) score . The score is a quartile ordinal grading scale used to compare the clinical findings before and after the treatment, so a score of one means an improvement of 25% and a score of ‐1 means a worsening of 25%, and changes move from 0 (no change) at baseline.…”

Section: Methodsmentioning

confidence: 99%

“…Pulsed‐dye laser (PDL) has been reported to provide better outcomes for inflammatory dermatoses, namely acne, discoid lupus erythematosus and nail psoriasis . Typically, PDL, with wavelengths of 585 and 595 nm, is used to treat vascular lesions.…”

Section: Introductionmentioning

confidence: 99%

Pulsed‐dye laser as an adjuvant treatment for papulopustular eruptions from epidermal growth factor receptor inhibitors, a randomized blinded split‐faced controlled trial

et al. 2019

Self Cite

View full text Add to dashboard Cite

Objectives To investigate the efficacy of pulsed‐dye laser (PDL) as an adjunctive treatment for facial papulopustular eruptions from EGFR inhibitors (EGFRi). Methods Fourteen patients with facial acneiform eruptions were recruited. Half side of the face was randomized to receive PDL treatment while the other side served as a control. The treatments were delivered every 2 weeks for 4 sessions. The patients were seen at baseline, weeks 2, 4, 6, 8, and 10. Erythema index (EI) measured by colorimeter, the papulopustular lesion count and physician global assessment (PGA) were obtained. Patients were allowed to use their standard treatments for their eruptions. Results Both arms had a significant decrease in EI from baseline at each subsequent visit. In the laser treated side, the mean (95%CI) EI decreased from 23.5 (22.24–24.76) at baseline to 16.3 (15.01–17.59) at week 10, while those of the sham were 23.49 (22.23–24.75) to 20.51 (19.22–21.8), respectively. The mean change was significantly lower in the PDL arm from week 4 onwards. The lesion counts in both groups also decreased significantly, but the mean difference between the arms was not different. PGA scores followed the same pattern as EI. Conclusions Adjunctive treatment with PDL was a safe and effective treatment. Lasers Surg. Med. © 2019 Wiley Periodicals, Inc.

show abstract

Pulsed-dye laser as an adjuvant treatment for discoid lupus erythematosus: a randomized, controlled trial

Abstract: Improvements of DLE can be achieved with PDL.

Cited by 19 publications

References 20 publications

Nonvascular uses of pulsed dye laser in clinical dermatology

Nonvascular uses of pulsed dye laser in clinical dermatology

Current Concepts and Future Approaches in the Treatment of Cutaneous Lupus Erythematosus: A Comprehensive Review

Pulsed‐dye laser as an adjuvant treatment for papulopustular eruptions from epidermal growth factor receptor inhibitors, a randomized blinded split‐faced controlled trial

Contact Info

Product

Resources

About